Edoxaban prevented adverse effects including pyrexia and elevation of D‐dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF‐mutant melanoma-Reference-Cited by-同舟云学术

Edoxaban prevented adverse effects including pyrexia and elevation of D‐dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF‐mutant melanoma

Published:2021-02-18 Issue:5 Volume:48 Page:707-709
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J. Dermatol.

Author:

Mukai Kei¹,Kamata Masahiro¹^ORCID,Miyazaki Mirei¹,Nagata Mayumi¹,Fukaya Saki¹,Hayashi Kotaro¹,Fukuyasu Atsuko¹,Ishikawa Takeko¹,Ohnishi Takamitsu¹,Tada Yayoi¹^ORCID,Tanaka Takamitsu¹

Affiliation:

1. Department of Dermatology Teikyo University School of Medicine Tokyo Japan

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.15813

Reference8 articles.

1. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

2. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

3. Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma

4. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

5. Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential drug–drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma;Expert Opinion on Drug Metabolism & Toxicology;2023-08-03

2. Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond;International Journal of Molecular Sciences;2021-09-13

3. Multiple drugs;Reactions Weekly;2021-06